3rd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Period 3rd Quarter 2010 Filed Oct 20, 2010 Signed by Paul J. Larsen - Deputy Compliance Officer & Assistant General Counsel

Official filing
Firm
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Client
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Income
—
Expenses
$5,180,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements Korea Free Trade Agreement: intellectual property, market access and public health Trans-Pacific Strategic Economic Partnership Agreement (TPP): intellectual property issues Special 301 submission Preference Program Reform International market access and intellectual property issues Trade enforcement issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI New —
ROBERT FILIPPONE —
LEA FISHER —
MATTHEW L SULKALA —

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Office of Natl Drug Control Policy (NDCP); Office of Management & Budget (OMB); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Internal Revenue Service (IRS); Congressional Budget Office (CBO); Patent & Trademark Office (PTO)

Bills named: H.R. 3012 (111th)

Copyright/Patent/Trademark CPT

H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements International intellectual property issues

LobbyistCovered position, as disclosed
DAVID BOYER —
ROBERT FILIPPONE —
LEA FISHER —
JAMES BRYANT HALL —
DAVID KORN —
KENDRA MARTELLO —
TOM MOORE —
BRIAN NAGLE —
ANNE PRITCHETT —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
STEVE TILTON —

Contacted: Commerce, Dept of (DOC); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS); White House Office; Food & Drug Administration (FDA); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); Office of Natl Drug Control Policy (NDCP); Health Resources & Services Administration (HRSA); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 1706 (111th), S. 3677 (111th), H.R. 573 (111th), H.R. 5322 (111th), S. 515 (111th), S. 501 (111th), H.R. 4899 (111th), S. 610 (111th), H.R. 1260 (111th), S. 369 (111th), H.R. 4213 (111th)

Health Issues HCR

H.R. 422, Heart Disease Education, Analysis Research, and Treatment for Women Act: R&D tax credit provisions H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues H.R. 1032, Heart Disease Education, Analysis Research, and Treatment for Women Act: clinical trial data reporting issues H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, drug labeling, access to clinical trials, health reform fee, Independent Payment Advisory Board (IPAB) and other health reform implementation issues H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: 340B program and average manufacturer price (AMP) issues H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act: transparency of drug pricing H.R. 4872, Health Care and Education Reconciliation Act of 2010: 340B program and health reform fee issues H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1203, Grow Research Opportunities With Taxcredits' Help Act: R&D tax credit provisions S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1679, Affordable Health Choices Act: 340B program issues, importation, and other health reform implementation issues S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances General FDA advocacy

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER —
RANDY BURKHOLDER —
JOHN J CASTELLANI New —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM —
LEA FISHER —
GREGORY GIERER —
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
HALLIE AMANDA MARANCHICK —
KENDRA MARTELLO —
TOM MOORE —
BRIAN NAGLE —
ANNE PRITCHETT —
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON —
STEVE TILTON —
MICHAEL PAUL WOODY —

Contacted: U.S. Trade Representative (USTR); White House Office; Office of Natl Drug Control Policy (NDCP); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); SENATE; State, Dept of (DOS); Internal Revenue Service (IRS); Office of Management & Budget (OMB); Agency for Healthcare Research & Quality (AHRQ); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 444 (111th), S. 3397 (111th), H.R. 3590 (111th), H.R. 4213 (111th), H.R. 5710 (111th), S. 1679 (111th), H.R. 422 (111th), S. 1213 (111th), S. 1203 (111th), S. 525 (111th), H.R. 2502 (111th), H.R. 2824 (111th), S. 1232 (111th), H.R. 1032 (111th), H.R. 5809 (111th), H.R. 1298 (111th), H.R. 4489 (111th), H.R. 4872 (111th)

Medicare/Medicaid MMM

H.R. 1586, FAA Air Transportation Modernization and Safety Improvements: AMP issues H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, Part D coverage gap discounts, Part D issues generally, Medicare payment issues including the Independent Payment Advisory Board (IPAB), and Medicaid issues H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: non-interference provisions H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: average manufacturer price (AMP) issues H.R. 4872, Health Care and Education Reconciliation Act of 2010: Part D coverage gap discounts, Part D issues generally, Medicaid rebate issues, health reform fee, and other health reform implementation issues generally H.R. 4899, Supplemental Appropriations Act, 2010: AMP issues

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER —
RANDY BURKHOLDER —
JOHN J CASTELLANI New —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM —
LEA FISHER —
GREGORY GIERER —
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
ANN KAPLAN —
TOM MOORE —
BRIAN NAGLE —
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON —
STEVE TILTON —
MICHAEL PAUL WOODY —

Contacted: Commerce, Dept of (DOC); Internal Revenue Service (IRS); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); White House Office; Congressional Budget Office (CBO); State, Dept of (DOS)

Bills named: H.R. 4752 (111th), H.R. 4872 (111th), H.R. 4213 (111th), H.R. 3590 (111th), H.R. 1586 (111th), H.R. 4899 (111th)

Budget/Appropriations BUD

H.RES. 1493, Providing for budget enforcement for fiscal year 2011: budget provisions S. 3606, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2011: FDA funding

LobbyistCovered position, as disclosed
DAVID BOYER —
JOHN J CASTELLANI New —
LEA FISHER —
VALERIE HARDIN JEWETT —
BRIAN NAGLE —
LORI REILLY —
MATTHEW L SULKALA —
STEVE TILTON —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; White House Office; Office of Management & Budget (OMB); Office of Natl Drug Control Policy (NDCP); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Agency for Healthcare Research & Quality (AHRQ); Congressional Budget Office (CBO); Internal Revenue Service (IRS)

Bills named: H.Res. 1493 (111th), S. 3606 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.